Thalidomide-based Regimens: Rates of VTE* in Newly Diagnosed MM Treatment No Prophylaxis Any Prophylaxis ASA Warfarin 1-1.25 mg/d Prophylactic LMWH Therapeutic.

Slides:

Advertisements

Similar presentations

Farmaci usati prima dellintervento Basi farmacologiche del loro uso La prevenzione del tromboembolismo.

Advertisements

Evidence-Based Management of Anticoagulant Therapy

Prosthetic Valve; Anticoagulation After ICH Dr.Tahsin.N.

Venous Thromboembolism Prevention August Venous Thromboembloism Prevention 2 Expected Practice  Assess all patients upon admission to the ICU for.

Venous Thromboembolism (VTE) Prophylaxis Policy Mary-Anne Davies Patient Safety Specialist Accreditation Coordinator.

Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.

Medications that impact bleeding By Nino Lalaiants Inesa Legrian NYCCT 2012.

Palumbo A et al. Proc ASH 2012;Abstract 446.

1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.

CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.

Venous thromboembolism: how long to treat?

LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.

Vascular issues associated with bevacizumab Stuart M. Lichtman, MD, FACP 65+ Clinical Geriatric Program Associate Attending Memorial Sloan-Kettering Cancer.

Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.

Bridging Oral Anticoagulation with Low Molecular Weight Heparin: Experience in 367 Patients with Renal Insufficiency Heyder Omran, Giso von der Recke,

Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer Agnelli G et al. N Engl J Med 2012;366(7): George D et al. Proc.

Venous Thromboembolism

Complicanze trombotiche nel mieloma multiplo Mauro Berrettini S.C. Medicina Generale-DH Oncologico Ospedale di Orvieto Mediterranean School of Oncology.

DVT Prevention and Anticoagulant Management

Warfarin Efficacy in Cancer Patients on Long-term Anticoagulation Neha Doshi, PharmD Candidate LeAnn B. Norris, PharmD, BCPS P. Brandon Bookstaver, PharmD,

Deep vein thrombosis Pulmonary embolism Deep vein thrombosis Pulmonary embolism Venous Thromboembolism TreatmentTreatment …All the same?

Oral Rivaroxaban for Symptomatic Venous Thromboembolism.

A Randomized Trial of Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism Schulman S et al. Proc ASH 2011;Abstract 205.

Dose-Escalated Low Molecular Weight Heparin Provides Effective Anticoagulation for Women with Mechanical Heart Valves During Pregnancy: A Single-Centre.

Treatment Multiple Myeloma. Symptomatic/progressive myeloma: Systemic therapy - to control progression of myeloma Supportive care - to prevent serious.

Peri-Operative anticoagulation /antiplatelet therapy A Shift in Paradigm BMHGT04/29/09.

Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.

Previous thrombotic events? aspirin + LMW(H) * long-term use of low dose aspirin? YES aspirin; consider + (LMW)H * LMW(H) * LMW(H) * ; oral anticoagulants.

Agents Affecting Blood Clotting

Coagulation Modifier Agents Lilley Pharmacology Text: Chapter 26 Original Text modified by: Anita A. Kovalsky, R.N., M.N.Ed. Professor of Nursing Original.

Postpartum period in women with systemic lupus erythematosus BY DR KH ELMIZADEH.

MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.

Venous thrombosis , why should I care ?

Evidence-Based Management of Anticoagulant Therapy

Clinical Professor in Palliative Medicine

Presenter: Meng-Jiun Chiou Present data: 2017/7/10

Multiple Myeloma in the Non-transplant Setting

By: Dr. Nalaka Gunawansa

Volume 130, Issue 6, Pages (December 2006)

Ortho Warfarin Dosing Protocol

Fatimah Al-Ani 1,2,. MD MRCP, Jose Maria Bastida Bermejo3,

Copyright © 2000 American Medical Association. All rights reserved.

Russell D. Hull, MBBS, MSc, Graham F. Pineo, MD, Rollin F

Perspectives on Triple-Negative Breast Cancer

Thrombosis, Cancer, and NOACs

Module 3 REDUCE THE LIKELIHOOD OF PATIENT HARM ASSOCIATED WITH THE USE OF ANTICOAGULANT THERAPY.

Paul D. Stein, MD, Russell D. Hull, MBBS, MSc, Fadi Matta, MD, Abdo Y

Issues in the Management of Hemophilia: A Best Practice Series

Selecting MM Therapy in Patients With Comorbidities

The effectiveness of anticoagulant and antiplatelet agents in preventing venous thromboembolism during stroke rehabilitation: a historical cohort study.

Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.

A Better Solution For Cancer Patients With VTE?

Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Russell D. Hull, MBBS, MSc, Graham F. Pineo, MD, Rollin F

Staying Abreast of Best Practices Across the Clinical Continuum

Cancer-Associated Thrombosis

by Alex C. Spyropoulos, and James D. Douketis

ONLY oral unit-dose warfarin, prefilled Fragmin syringes, and premixed heparin drips are used at CHSB.

Extraordinary Cases in VTE

How I treat cancer-associated venous thromboembolism

Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.

Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.

Thrombophilia in pregnancy: Whom to screen, when to treat

(p for noninferiority = 0.01)

QUALITY: SAFE CARE Potentially Preventable Adverse Events and Complications of Care in Hospitals Among Medicare Beneficiaries, 2004–2005 Percent *Surgical.

Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.

Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.

Presentation transcript:

Thalidomide-based Regimens: Rates of VTE* in Newly Diagnosed MM Treatment No Prophylaxis Any Prophylaxis ASA Warfarin mg/d Prophylactic LMWH Therapeutic Anticoagulation T alone (95% CI) 1.3 (0.4–2.7) (n=380) NA 0.5 (0.4–0.6) (n=64) NA TD (95% CI) 4.1 (2.8–5.9) (n=628) 2.6 (2.1–3.2) (n=993) 2.3 (0.9–7.9) (n=80) 2.8 (2–3.9) (n=387) 2.1 (1.1–3.6) (n=446) 1.6 (0.2–4.1) (n=80) *per 100 patient-cycles ASA=aspirin; LMWH=low molecular weight heparin; MM=multiple myeloma; T=thalidomide; TD=thalidomide + dexamethasone; VTE=venous thromboembolism 1090

Thalidomide-based Regimens: Rates of VTE* in Previously Treated MM TreatmentNo prophylaxisASA Warfarin mg/d Prophylactic LMWH Therapeutic Doses of Anticoagulation T alone (95% CI) 0.4 (0.2–0.8) (n=706) NA 0 (0–1.72) (n=17) NA T+ prednisone (95% CI) 0.6 (0.2–1.1) (n=258) NA TC (95% CI) 0.4 (0.01–1.2) (n=38) 0.4 (0.01–0.9) (n=37) NA TD (95% CI) 0.8 (0.1–2.1) (n=321) NA TDC agents (95% CI) 0.9 (0.3–1.8) (n=321) NA 2.4 (1.3–4) (n=102) NA 0 (0–2.2) (n=18) TDC including doxorubicin (95% CI) 6.7 (0.5–18.9) (n=331) NA 3.5 (1.2–6.5) (n=50) NA Lenalidomide-based regimens *per 100 patient-months ASA=aspirin; LMWH=low molecular weight heparin; MM=multiple myeloma; T=thalidomide; TC=thalidomide + cytotoxic chemotherapy; TD=thalidomide + dexamethasone; TDC=thalidomide + dexamethasone + cytotoxic chemotherapy; VTE=venous thromboembolism 1090

Lenalidomide-based Regimens Rates of VTE (per 100 patient-cycles) in patients with newly diagnosed MM TreatmentNo ProphylaxisAny ProphylaxisASA LD (95% CI) 0.8 (0.07–2) (n=278) 0.7 (0.5–1.1) (n=349) 0.9 (0.5–1.5) (n=172) Rate of VTE (per 100 patient-months) in patients with previously treated MM TreatmentNo ProphylaxisASA LD (95% CI) 0.7 (0.4–0.9) (n=361) NA LDC including doxorubicin (95% CI) NA 0.6 (0.01–2.1) (n=131) None of the studies reported major bleeding events. ASA=aspirin; LD=lenalidomide + dexamethasone; VTE=venous thromboembolism 1090